Identification of glioblastoma-specific antigens expressed in patient-derived tumor cells as candidate targets for chimeric antigen receptor T cell therapy. Issue 1 (15th November 2022)

• Record Type: Journal Article
• Authors: Nakagawa, Tomoyoshi; Kijima, Noriyuki; Hasegawa, Kana; Ikeda, Shunya; Yaga, Moto; Wibowo, Tansri; Tachi, Tetsuro; Kuroda, Hideki; Hirayama, Ryuichi; Okita, Yoshiko; Kinoshita, Manabu; Kagawa, Naoki; Kanemura, Yonehiro; Hosen, Naoki; Kishima, Haruhiko
• Is Part Of: Neuro-oncology advances. Volume 5:Issue 1(2023)
• Publication Date: 2022-11-15
• Subjects: B7-H3 -- CAR-T cell therapy -- expression cloning -- glioblastoma (GBM) -- monoclonal antibody; 616.99481
• DOI: 10.1093/noajnl/vdac177
• Languages: English
• ISSNs: 2632-2498

Abstract

Abstract: Background: New therapies for glioblastoma (GBM) are urgently needed because the disease prognosis is poor. Chimeric antigen receptor (CAR)-T cell therapy that targets GBM-specific cell surface antigens is a promising therapeutic strategy. However, extensive transcriptome analyses have uncovered few GBM-specific target antigens. Methods: We established a library of monoclonal antibodies (mAbs) against a tumor cell line derived from a patient with GBM. We identified mAbs that reacted with tumor cell lines from patients with GBM but not with nonmalignant human brain cells. We then detected the antigens they recognized using expression cloning. CAR-T cells derived from a candidate mAb were generated and tested in vitro and in vivo . Results: We detected 507 mAbs that bound to tumor cell lines from patients with GBM. Among them, E61 and A13 reacted with tumor cell lines from most patients with GBM, but not with nonmalignant human brain cells. We found that B7-H3 was the antigen recognized but E61. CAR-T cells were established using the antigen-recognition domain of E61-secreted cytokines and exerted cytotoxicity in co-culture with tumor cells from patients with GBM. Conclusions: Cancer-specific targets for CAR-T cells were identified using a mAb library raised against primary GBM tumor cells from a patient. We identified a GBM-specific mAb and its antigen. More mAbs against various GBM samples and novel target antigens are expected to be identified using this strategy.